JP2016516761A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516761A5 JP2016516761A5 JP2016507058A JP2016507058A JP2016516761A5 JP 2016516761 A5 JP2016516761 A5 JP 2016516761A5 JP 2016507058 A JP2016507058 A JP 2016507058A JP 2016507058 A JP2016507058 A JP 2016507058A JP 2016516761 A5 JP2016516761 A5 JP 2016516761A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- pharmaceutically acceptable
- nalidixic acid
- acceptable salt
- analog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 claims description 51
- 150000003839 salts Chemical class 0.000 claims description 49
- 229960000210 nalidixic acid Drugs 0.000 claims description 45
- 150000001875 compounds Chemical class 0.000 claims description 31
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 208000030533 eye disease Diseases 0.000 claims description 19
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 9
- 206010013774 Dry eye Diseases 0.000 claims description 9
- 206010038886 Retinal oedema Diseases 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 238000011200 topical administration Methods 0.000 claims description 7
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 230000001575 pathological effect Effects 0.000 claims description 5
- 206010058202 Cystoid macular oedema Diseases 0.000 claims description 4
- 208000001351 Epiretinal Membrane Diseases 0.000 claims description 4
- 208000001344 Macular Edema Diseases 0.000 claims description 4
- 208000031471 Macular fibrosis Diseases 0.000 claims description 4
- 206010029113 Neovascularisation Diseases 0.000 claims description 4
- -1 O-alkyl Chemical group 0.000 claims description 4
- 201000010183 Papilledema Diseases 0.000 claims description 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 4
- 201000010206 cystoid macular edema Diseases 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 201000011195 retinal edema Diseases 0.000 claims description 4
- 230000002207 retinal effect Effects 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 206010010741 Conjunctivitis Diseases 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 206010046851 Uveitis Diseases 0.000 claims description 3
- 239000000739 antihistaminic agent Substances 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 102400000068 Angiostatin Human genes 0.000 claims description 2
- 108010079709 Angiostatins Proteins 0.000 claims description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims description 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 2
- 206010010755 Conjunctivitis viral Diseases 0.000 claims description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 2
- 229930105110 Cyclosporin A Natural products 0.000 claims description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 claims description 2
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 2
- 208000002367 Retinal Perforations Diseases 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 208000005914 Viral Conjunctivitis Diseases 0.000 claims description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 230000000844 anti-bacterial effect Effects 0.000 claims description 2
- 229940125715 antihistaminic agent Drugs 0.000 claims description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 2
- 201000007032 bacterial conjunctivitis Diseases 0.000 claims description 2
- 229940092705 beclomethasone Drugs 0.000 claims description 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims description 2
- 229960002537 betamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims description 2
- 229960004436 budesonide Drugs 0.000 claims description 2
- 229960001803 cetirizine Drugs 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 229960004544 cortisone Drugs 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229960001259 diclofenac Drugs 0.000 claims description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 2
- 229960002390 flurbiprofen Drugs 0.000 claims description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 2
- 229960002714 fluticasone Drugs 0.000 claims description 2
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 2
- 229960000890 hydrocortisone Drugs 0.000 claims description 2
- 229960004752 ketorolac Drugs 0.000 claims description 2
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 2
- 229960004958 ketotifen Drugs 0.000 claims description 2
- 150000002617 leukotrienes Chemical class 0.000 claims description 2
- 229960003088 loratadine Drugs 0.000 claims description 2
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 2
- 208000029233 macular holes Diseases 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 229960001810 meprednisone Drugs 0.000 claims description 2
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims description 2
- 229960004584 methylprednisolone Drugs 0.000 claims description 2
- 229960001664 mometasone Drugs 0.000 claims description 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 2
- 230000000649 photocoagulation Effects 0.000 claims description 2
- 229960005205 prednisolone Drugs 0.000 claims description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims description 2
- 229960000241 vandetanib Drugs 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003862 glucocorticoid Substances 0.000 claims 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 3
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 150000005671 trienes Chemical class 0.000 claims 1
- MWLSOWXNZPKENC-SSDOTTSWSA-N zileuton Chemical compound C1=CC=C2SC([C@H](N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-SSDOTTSWSA-N 0.000 claims 1
- 229960005332 zileuton Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201306411A GB201306411D0 (en) | 2013-04-09 | 2013-04-09 | Treatment of inflammatory conditions |
| GB1306411.8 | 2013-04-09 | ||
| GB201306413A GB201306413D0 (en) | 2013-04-09 | 2013-04-09 | The local treatment of ophthalmic diseases |
| GB1306413.4 | 2013-04-09 | ||
| PCT/GB2014/051108 WO2014167326A1 (en) | 2013-04-09 | 2014-04-09 | The local treatment of inflammatory ophthalmic diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016516761A JP2016516761A (ja) | 2016-06-09 |
| JP2016516761A5 true JP2016516761A5 (https=) | 2017-06-01 |
Family
ID=50489339
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016507059A Pending JP2016516762A (ja) | 2013-04-09 | 2014-04-09 | 炎症性障害の治療 |
| JP2016507058A Pending JP2016516761A (ja) | 2013-04-09 | 2014-04-09 | 炎症性眼疾患の局所治療 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016507059A Pending JP2016516762A (ja) | 2013-04-09 | 2014-04-09 | 炎症性障害の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20160068527A1 (https=) |
| EP (2) | EP2983713A1 (https=) |
| JP (2) | JP2016516762A (https=) |
| CN (2) | CN105431172A (https=) |
| AU (2) | AU2014252808A1 (https=) |
| CA (2) | CA2909111A1 (https=) |
| GB (2) | GB2516137B (https=) |
| HK (2) | HK1221166A1 (https=) |
| RU (2) | RU2015145134A (https=) |
| WO (2) | WO2014167326A1 (https=) |
| ZA (2) | ZA201507718B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104496986A (zh) * | 2014-12-12 | 2015-04-08 | 苏州亚科化学试剂股份有限公司 | 萘啶酸的制备方法 |
| JP6474913B2 (ja) * | 2015-10-29 | 2019-02-27 | テイカ製薬株式会社 | 外用剤 |
| US11510931B2 (en) | 2016-09-28 | 2022-11-29 | Medicon Pharmaceuticals, Inc. | Compositions and methods for treating ophthalmic conditions |
| WO2020021035A1 (en) * | 2018-07-26 | 2020-01-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of antibiotics for the treatment of immunoglobulin a nephropathy |
| WO2020163816A1 (en) * | 2019-02-08 | 2020-08-13 | Frequency Therapeutics, Inc. | Quinolin-4-one and 4(1h)-cinnolinone compounds and methods of using same |
| FI4027983T3 (fi) * | 2019-09-11 | 2026-02-03 | Adverum Biotechnologies Inc | Silmän neovaskulaaristen sairauksien hoito afliberseptiä koodaavilla aav2-varianteilla |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19633480A1 (de) * | 1996-08-20 | 1998-02-26 | Bayer Ag | Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren |
| ID23053A (id) * | 1997-06-04 | 2000-01-20 | Lilly Co Eli | Karboksamida yang digunakan sebagai agonis 5-ht <if> |
| DE19729879C2 (de) * | 1997-07-11 | 1999-07-08 | Mann Gerhard Chem Pharm Fab | Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin |
| DE19826050A1 (de) * | 1998-06-12 | 1999-12-16 | Bayer Ag | Verfahren zur Herstellung von Chinolon- und Naphthyridoncarbonsäuren und deren Ester |
| CN1090959C (zh) * | 1999-06-17 | 2002-09-18 | 卢世全 | 一种治疗咳喘病的中、西复方成药及制备方法 |
| US6552020B1 (en) * | 1999-07-30 | 2003-04-22 | Allergan, Inc. | Compositions including antibiotics and methods for using same |
| JP2001342188A (ja) * | 2000-03-27 | 2001-12-11 | Takeda Chem Ind Ltd | 縮合ピラゾール誘導体、その製造法および用途 |
| JP3648132B2 (ja) * | 2000-06-19 | 2005-05-18 | 大正薬品工業株式会社 | キノロン系抗菌薬液体製剤及びその包装体 |
| WO2003004098A1 (en) * | 2001-07-06 | 2003-01-16 | Sucampo Ag | Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| AUPS017702A0 (en) * | 2002-01-25 | 2002-02-14 | Atopic Pty Ltd | Methods and compositions for the treatment of asthma and related disorders |
| CA2928387A1 (en) * | 2004-05-03 | 2005-11-17 | Merrimack Pharmaceuticals, Inc. | Drug delivery liposomes containing anionic polyols or anionic sugars |
| RS56037B1 (sr) * | 2004-06-24 | 2017-09-29 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
| JP2006028031A (ja) * | 2004-07-12 | 2006-02-02 | Ltt Bio-Pharma Co Ltd | 経粘膜吸収用薬物封入ナノ粒子 |
| EP2452670A1 (en) * | 2004-10-01 | 2012-05-16 | Ramscor, Inc. | Conveniently implantable sustained release drug compositions |
| CA2631773C (en) * | 2005-12-02 | 2022-04-26 | Health Enhancement Products, Inc. | Composition and use of phyto-percolate for treatment of disease |
| US20080138350A1 (en) * | 2006-10-20 | 2008-06-12 | Bennett Michael D | Process for use of fluoroquinolones to reduce or modulate inflammation due to eye disease or ophthalmic surgery |
| CN101129386A (zh) * | 2007-07-17 | 2008-02-27 | 长治市三宝生化药业有限公司 | 一种含环丙沙星和地塞米松的局部悬浮滴眼剂 |
| JPWO2009037855A1 (ja) * | 2007-09-21 | 2011-01-06 | 株式会社日本高度医療研究会 | 口腔用及び皮膚用組成物 |
| GB0719518D0 (en) * | 2007-10-05 | 2007-11-14 | Therapeutics Ltd E | Therapy |
| ES2575954T3 (es) * | 2007-10-11 | 2016-07-04 | The Regents Of The University Of California | Composiciones y métodos de inhibición de la amidasa ácida hidrolizante de la N-aciletanolamina |
| MX342183B (es) * | 2008-09-09 | 2016-09-20 | Allergan Inc | Suspension oftalmica para uso ocular. |
| EP2346509B1 (en) * | 2008-10-07 | 2020-05-13 | Horizon Orphan LLC | Inhalation of levofloxacin for reducing lung inflammation |
| BR112012003453A2 (pt) * | 2009-08-19 | 2019-09-24 | Mpex Pharmaceuticals Inc | metodo para reduzir taxa de exacerbações agudas de um distúrbio pulmonar: uso de um aerosol de uma solução que comreende levofloxacina ou ofloxacina; método para aumentar o periodo de tempo entre as exaberações agudas de um disturbio pulmonar; uso de um aerossol de uma solução que compreende levofloxacina ou ofloxacina; método para aumentar o período de tempo entre as exacerbações agudas de um distúrbio pulmonar; método para reduzir a taxa de hospitalizações relacionadas ao sistema respiratório de uma população de seres humanos que tem um distúrbio; uso de um aerossol de uma solução que compreende levofloxacina; método, uso ou aerossol. |
| US20130079353A1 (en) * | 2009-12-22 | 2013-03-28 | Karsten Gülow | Fluoroquinolones for the treatment and/or prophylaxis of inflammatory diseases |
| MX346312B (es) * | 2011-04-05 | 2017-03-15 | Optosolve Res & Dev Ltd | Tratamientos oftalmicos. |
-
2014
- 2014-04-09 AU AU2014252808A patent/AU2014252808A1/en not_active Abandoned
- 2014-04-09 WO PCT/GB2014/051108 patent/WO2014167326A1/en not_active Ceased
- 2014-04-09 JP JP2016507059A patent/JP2016516762A/ja active Pending
- 2014-04-09 EP EP14717821.4A patent/EP2983713A1/en not_active Withdrawn
- 2014-04-09 HK HK16109377.6A patent/HK1221166A1/zh unknown
- 2014-04-09 JP JP2016507058A patent/JP2016516761A/ja active Pending
- 2014-04-09 CN CN201480030407.7A patent/CN105431172A/zh active Pending
- 2014-04-09 EP EP14717820.6A patent/EP2983788A1/en not_active Withdrawn
- 2014-04-09 RU RU2015145134A patent/RU2015145134A/ru not_active Application Discontinuation
- 2014-04-09 GB GB1406390.3A patent/GB2516137B/en active Active
- 2014-04-09 WO PCT/GB2014/051109 patent/WO2014167327A1/en not_active Ceased
- 2014-04-09 US US14/782,975 patent/US20160068527A1/en not_active Abandoned
- 2014-04-09 HK HK16109376.7A patent/HK1221190A1/zh unknown
- 2014-04-09 GB GB1406396.0A patent/GB2516138C/en active Active
- 2014-04-09 CA CA2909111A patent/CA2909111A1/en not_active Abandoned
- 2014-04-09 CN CN201480030418.5A patent/CN105555364A/zh active Pending
- 2014-04-09 US US14/783,038 patent/US20160051526A1/en not_active Abandoned
- 2014-04-09 AU AU2014252807A patent/AU2014252807A1/en not_active Abandoned
- 2014-04-09 CA CA2909117A patent/CA2909117A1/en not_active Abandoned
- 2014-04-09 RU RU2015145135A patent/RU2015145135A/ru not_active Application Discontinuation
-
2015
- 2015-10-15 ZA ZA201507718A patent/ZA201507718B/en unknown
- 2015-10-15 ZA ZA2015/07724A patent/ZA201507724B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516761A5 (https=) | ||
| JP2016528202A5 (https=) | ||
| JP2015528454A5 (https=) | ||
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| RU2015145134A (ru) | Местное лечение воспалительных офтальмологических заболеваний | |
| JP2015535293A5 (https=) | ||
| JP2009521493A (ja) | 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤 | |
| JP2006512318A5 (https=) | ||
| JP2009514969A5 (https=) | ||
| JP2017511793A5 (https=) | ||
| JP2016516762A5 (https=) | ||
| RU2018145017A (ru) | Применение сиролимуса для лечения экссудативной возрастной макулярной дегенерации с персистирующим отеком | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| PH12020551015A1 (en) | Medicine for preventing or treating ophthalmic disease associated with enhanced intraocular neovascularization and/or intraocular vascular permeability | |
| JP2019524679A5 (https=) | ||
| US20170224815A1 (en) | Method of Preventing and Treating Retinal Microvasculature Inflammation Using C-Met Signaling Pathway Inhibition | |
| Bikbov et al. | Intravitreal application of epidermal growth factor in non-exudative age-related macular degeneration | |
| JP2013501794A (ja) | 目の疾患を治療するためのイソチオゾール | |
| US20250387410A1 (en) | Treatment of anti-vegf refractory ophthalmic retinal eye conditions | |
| Testi et al. | Treatment of Uveitic Macular Edema | |
| de Zea et al. | Dexamethasone intravitreal implant for treatment of persistent macular oedema in Birdshot retinochoroidopathy | |
| CN104703606B (zh) | 1-金刚烷乙氧基-3-吗啉基-2-丙醇或其药学上可接受的盐在药物组合物中作为视神经网膜保护物使用 | |
| Arcinue et al. | Corticosteroids in uveitis | |
| JP2022537883A (ja) | エルトロンボパグの投与計画 | |
| NZ766013B2 (en) | Vitamin k2 compositions for the treatment of drug induced neuropathy |